Personalised to support your treatment decisions
Gilead Sciences and Galapagos announced Week 52 results from the Phase III FINCH 1 and FINCH 3 studies of GLPG 0634 (filgotinib), an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA).
Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine.
Inovio , the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/II clinical trial of INOVIO's COVID-19 vaccine INO 4800 in South Korea. The 2-stage trial of INO 4800, the first clinical study of COVID-19 vaccine in Korea, will assess the safety, tolerability, and immunogenicity of the candidate vaccine in 40 healthy adults aged 19-50 years, and will further expand toenroll an additional 120 people aged 19-64 years.